Literature DB >> 8071007

Some factors to consider when using the results of economic evaluation studies at the population level.

R M Leidl1.   

Abstract

The cost-effectiveness of a medical intervention at the population level may deviate from that reported for evaluations at the patient level. It is important for researchers and decision makers to know about the relevance of externalities, phasing-in effects, treatment effectiveness in the community, capacity issues, and different time perspectives in the evaluation of an intervention.

Entities:  

Mesh:

Year:  1994        PMID: 8071007     DOI: 10.1017/s0266462300006681

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

Review 1.  Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.

Authors:  R Baltussen; R Leidl; A Ament
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 2.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Enhancing prescription drug innovation and adoption.

Authors:  G Caleb Alexander; Alec B O'Connor; Randall S Stafford
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

5.  Generalized cost-effectiveness analysis for national-level priority-setting in the health sector.

Authors:  Raymond Hutubessy; Dan Chisholm; Tessa Tan-Torres Edejer
Journal:  Cost Eff Resour Alloc       Date:  2003-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.